Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

Benzinga · 2d ago
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.